GENB Generate Biomedicines, Inc.
Company Analysis
Latest News
🔴 Generate Biomedicines is trading 10.5% down
Generate Biomedicines is trading 10.5% down at $12.39 on October 13, 2026, with no clear company-specific catalyst identified. - A Seeking Alpha analysis of...
🔴 Generate Biomedicines is trading 5% down — specific trigger remains unclear
Generate Biomedicines is trading 5.27% lower at $13.11 on October 13, 2026; the specific trigger remains unclear. - No major company announcement or clearly...
🟢 Generate Biomedicines is trading 5% up today amid biotech-sector strength
Generate Biomedicines is trading at $14.74, up 5.36%, amid positive biotech-sector sentiment. - No new company-specific announcement was found for October 9;...
🟢 Generate Biomedicines is trading 5% up in pre-market
Generate Biomedicines is trading at $14.50, up 5.07% in pre-market on October 2, 2026; no clear catalyst has been identified. - On October 1, the company...
🔴 Generate Biomedicines is trading 4.3% down
Generate Biomedicines is trading at $14.38, down 4.29%, with no clear company-specific explanation identified for the October 1 decline. - The company’s...
🟢 Generate Biomedicines is trading 5% up in pre-market with no clear company-specific catalyst identified
Generate Biomedicines is trading 5.06% higher at $15.78 in pre-market, based on the provided pre-market price context; no clear company-specific catalyst has...
🟢 Generate Biomedicines is trading 5% up in pre-market — no clear catalyst identified
Generate Biomedicines is trading 5.38% higher at $16.25 in pre-market, with no clear catalyst identified for the September 30 move. - Available search results...
🔴 Generate Biomedicines is trading 4.85% down today with no clear catalyst identified
Generate Biomedicines is trading 4.85% lower at $15.21, amid continued biotech and growth-stock pressure, with no clearly confirmed direct catalyst. - It...
🔴 Generate Biomedicines is trading 5% down today amid broad biotech-sector pressure
Generate Biomedicines is trading 5.1% down at $15.68, pressured by broad biotech and growth-stock weakness. - No new company-specific announcement or...
🔴 Generate Biomedicines is trading 4.64% down today with no confirmed catalyst
Generate Biomedicines is trading at $16.65, down 4.64%, with no clearly confirmed catalyst for the decline. - At the Bernstein Healthcare Forum on September...
🟢 Generate Biomedicines is trading 11.45% up today amid a broad risk-on rebound
Generate Biomedicines is trading 11.45% up at $17.48, moving with a broad risk-on rebound rather than a clearly disclosed company-specific catalyst. - Biotech...
🟢 Generate Biomedicines is trading 10.01% up today as biotech joins broader risk-on rebound
Generate Biomedicines is trading 10.01% up now at $17.35 as biotech shares strengthen alongside a broader risk-on market rebound. - Biotech is up 2.55%, while...
🟢 Generate Biomedicines is trading 7.53% up today as biotech sector gains 2.55%
Generate Biomedicines is trading at $16.80, up 7.53% now, most likely reflecting biotech-sector strength and improved risk appetite. • Broader markets are...
🟢 Generate Biomedicines is trading 4.3% up today after Morgan Stanley conference highlighted AI-driven pipeline
Generate Biomedicines is trading 4.26% up at $16.39 after management presented at the Morgan Stanley Global Healthcare Conference on September 14, 2026. -...
🔴 Generate Biomedicines is trading 4.31% down today as Brent crude rose above $100
Generate Biomedicines is trading 4.31% down at $15.21 amid a broad market selloff as Brent crude rose above $100 amid intensifying U.S.-Iran tensions. - The...
🔴 Generate Biomedicines is trading 4.27% down today
Generate Biomedicines is trading 4.27% down at $15.69, with no clear company-specific negative catalyst identified for September 8, 2026. - The company...
🟢 Generate Biomedicines is trading 5.3% up today on positive GB-0895 asthma data
Generate Biomedicines is trading $16.63 (+5.32%) on September 2, 2026, after H.C. Wainwright raised its price target to $30 from $25 while maintaining a Buy...
🟢 Generate Biomedicines is trading 4.13% up today after H.C. Wainwright raised target to $30
Generate Biomedicines is trading 4.13% up at $15.90, outperforming a biotechnology sector down 4.24% on September 1, 2026, after H.C. Wainwright raised its...
Generate Biomedicines Target Hiked to $30, Following Positive Asthma Trial Results
H.C. Wainwright reiterated its Buy rating on Generate Biomedicines. The firm increased its price target to $30 from $25. The adjustment follows the early...
🔴 Generate Biomedicines falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...